Background: Observational evidence regarding the role of leptin in Alzheimer disease (AD) is conflicting. We sought to determine the causal role of circulating leptin and soluble plasma leptin receptor (sOB-R) levels in AD using a separate-sample Mendelian randomization study. Methods: Single nucleotide polymorphisms (SNPs) independently and solely predictive of log-transformed leptin (rs10487505 [LEP], rs780093 [GCKR], rs900400 [CCNL1], rs6071166 [SLC32A1], and rs6738627 [COBLL1]) and of sOB-R (rs1137101 [LEPR], rs2767485 [LEPR], and rs1751492 [LEPR]) levels (ng/mL) were obtained from 2 previously reported genome-wide association studies. We obtained associations of leptin and sOB-R levels with AD using inverse variance weighting with fixed effects by combining Wald estimates for each SNP. Sensitivity analyses included using weighted median and MR-Egger methods and repeating the analyses using only SNPs of genome-wide significance. Results: Using inverse variance weighting, genetically predicted circulating leptin levels were not associated with AD, albeit with wide confidence intervals (CIs): odds ratio (OR) 0.99 per log-transformed ng/mL; 95% CI 0.55-1.78. Similarly, the association of sOB-R with AD was null using inverse variance weighting (OR 1.08 per log-transformed ng/mL; 95% CI 0.83-1.41). Results from our sensitivity analyses confirmed our findings. Conclusions: In this first Mendelian randomization study estimating the causal effect of leptin on AD, we did not find an effect of genetically predicted circulating leptin and sOB-R levels on AD. As such, this study suggests that leptin is unlikely to be a major contributor to AD, although the wide CIs preclude a definitive assessment.

Keywords:
Alzheimer disease, Dementia, Leptin, Receptors, Leptin, Mendelian randomization analysis
1.
Cummings JL, Morstorf T, Zhong K: Alzheimer's disease drug-development pipeline: few candidates, frequent failures. Alzheimers Res Ther 2014;6:37.
2.
Johnston JM, Greco SJ, Hamzelou A, et al: Repositioning leptin as a therapy for Alzheimer's disease. Therapy 2011;8:481-490.
3.
Lieb W, Beiser AS, Vasan RS, et al: Association of plasma leptin levels with incident Alzheimer disease and MRI measures of brain aging. JAMA 2009;302:2565-2572.
4.
Khemka VK, Bagchi D, Bandyopadhyay K, et al: Altered serum levels of adipokines and insulin in probable Alzheimer's disease. J Alzheimers Dis 2014;41:525-533.
5.
Baranowska-Bik A, Bik W, Styczynska M, et al: Plasma leptin levels and free leptin index in women with Alzheimer's disease. Neuropeptides 2015;52:73-78.
6.
Johnston JM, Hu WT, Fardo DW, et al: Low plasma leptin in cognitively impaired ADNI subjects: gender differences and diagnostic and therapeutic potential. Curr Alzheimer Res 2014;11:165-174.
7.
Power DA, Noel J, Collins R, O'Neill D: Circulating leptin levels and weight loss in Alzheimer's disease patients. Dement Geriatr Cogn Disord 2001;12:167-170.
8.
Ma J, Zhang W, Wang HF, et al: Peripheral blood adipokines and insulin levels in patients with Alzheimer's disease: a replication study and meta-analysis. Curr Alzheimer Res 2016;13:223-233.
9.
Bigalke B, Schreitmuller B, Sopova K, et al: Adipocytokines and CD34 progenitor cells in Alzheimer's disease. PLoS One 2011;6:e20286.
10.
Zhou R, Deng J, Zhang M, et al: Association between bone mineral density and the risk of Alzheimer's disease. J Alzheimers Dis 2011;24:101-108.
11.
Niedowicz DM, Studzinski CM, Weidner AM, et al: Leptin regulates amyloid β production via the γ-secretase complex. Biochim Biophys Acta 2013;1832:439-444.
12.
Martins I, Gomes S, Costa RO, et al: Leptin and ghrelin prevent hippocampal dysfunction induced by Aβ oligomers. Neuroscience 2013;241:41-51.
13.
Li XL, Aou S, Oomura Y, et al: Impairment of long-term potentiation and spatial memory in leptin receptor-deficient rodents. Neuroscience 2002;113:607-615.
14.
Oomura Y, Hori N, Shiraishi T, et al: Leptin facilitates learning and memory performance and enhances hippocampal CA1 long-term potentiation and CaMK II phosphorylation in rats. Peptides 2006;27:2738-2749.
15.
Teunissen CE, van der Flier WM, Scheltens P, et al: Serum leptin is not altered nor related to cognitive decline in Alzheimer's disease. J Alzheimers Dis 2015;44:809-813.
16.
Oania R, McEvoy LK: Plasma leptin levels are not predictive of dementia in patients with mild cognitive impairment. Age Ageing 2015;44:53-58.
17.
Gustafson DR, Backman K, Lissner L, et al: Leptin and dementia over 32 years - The Prospective Population Study of Women. Alzheimers Dement 2012;8:272-277.
18.
Warren MW, Hynan LS, Weiner MF: Lipids and adipokines as risk factors for Alzheimer's disease. J Alzheimers Dis 2012;29:151-157.
19.
Theodoropoulou A, Metallinos IC, Psyrogiannis A, et al: Ghrelin and leptin secretion in patients with moderate Alzheimer's disease. J Nutr Health Aging 2012;16:472-477.
20.
Prasad V, Jorgenson J, Ioannidis JP, Cifu A: Observational studies often make clinical practice recommendations: an empirical evaluation of authors' attitudes. J Clin Epidemiol 2013;66:361-366.
21.
Neurotez, Inc. Pipeline. http://neurotez.com/pipeline/ (accessed November 23, 2016).
22.
Burgess S, Scott RA, Timpson NJ, et al: Using published data in Mendelian randomization: a blueprint for efficient identification of causal risk factors. Eur J Epidemiol 2015;30:543-552.
23.
Davey Smith G, Paternoster L, Relton C: When will Mendelian randomization become relevant for clinical practice and public health? JAMA 2017;317:589-591.
24.
Kilpelainen TO, Carli JF, Skowronski AA, et al: Genome-wide meta-analysis uncovers novel loci influencing circulating leptin levels. Nat Commun 2016;7:10494.
25.
Sun Q, Cornelis MC, Kraft P, et al: Genome-wide association study identifies polymorphisms in LEPR as determinants of plasma soluble leptin receptor levels. Hum Mol Genet 2010;19:1846-1855.
26.
Lambert JC, Ibrahim-Verbaas CA, Harold D, et al: Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nat Genet 2013;45:1452-1458.
27.
Fieller EC: Some problems in interval estimation. J R Stat Soc Series B 1954;16:175-185.
28.
Bowden J, Davey Smith G, Haycock PC, Burgess S: Consistent estimation in Mendelian randomization with some invalid instruments using a weighted median estimator. Genet Epidemiol 2016;40:304-314.
29.
Bowden J, Davey Smith G, Burgess S: Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. Int J Epidemiol 2015;44:512-525.
30.
Li MX, Gui HS, Kwan JS, Sham PC: GATES: a rapid and powerful gene-based association test using extended Simes procedure. Am J Hum Genet 2011;88:283-293.
31.
Lammert A, Kiess W, Bottner A, et al: Soluble leptin receptor represents the main leptin binding activity in human blood. Biochem Biophys Res Commun 2001;283:982-988.
32.
Chan JL, Bluher S, Yiannakouris N, et al: Regulation of circulating soluble leptin receptor levels by gender, adiposity, sex steroids, and leptin: observational and interventional studies in humans. Diabetes 2002;51:2105-2112.
33.
Hellström L, Wahrenberg H, Hruska K, et al: Mechanisms behind gender differences in circulating leptin levels. J Intern Med 2000;247:457-462.
34.
Rice T, Chagnon YC, Borecki IB, et al: Familial resemblance for plasma leptin: sample homogeneity across adiposity and ethnic groups. Obes Res 2002;10:351-360.
35.
Mishra S, Harris TB, Hsueh WC, et al: The association of serum leptin with mortality in older adults. PLoS One 2015;10:e0140763.
36.
Batsis JA, Sahakyan KR, Singh P, et al: Leptin, adiposity, and mortality: results from the National Health and Nutrition Examination Survey III, 1988 to 1994. Mayo Clin Proc 2015;90:481-491.
37.
Brion MJ, Shakhbazov K, Visscher PM: Calculating statistical power in Mendelian randomization studies. Int J Epidemiol 2013;42:1497-1501.
38.
Shimizu H, Shimomura Y, Hayashi R, et al: Serum leptin concentration is associated with total body fat mass, but not abdominal fat distribution. Int J Obes Relat Metab Disord 1997;21:536-541.
39.
Liuzzi A, Savia G, Tagliaferri M, et al: Serum leptin concentration in moderate and severe obesity: relationship with clinical, anthropometric and metabolic factors. Int J Obes Relat Metab Disord 1999;23:1066-1073.
40.
Lee JH, Reed DR, Price RA: Leptin resistance is associated with extreme obesity and aggregates in families. Int J Obes Relat Metab Disord 2001;25:1471-1473.
41.
Tolppanen AM, Ngandu T, Kåreholt I, et al: Midlife and late-life body mass index and late-life dementia: results from a prospective population-based cohort. J Alzheimers Dis 2014;38:201-209.
42.
Mukherjee S, Walter S, Kauwe JS, et al: Genetically predicted body mass index and Alzheimer's disease-related phenotypes in three large samples: Mendelian randomization analyses. Alzheimers Dement 2015;11:1439-1451.
43.
White H, Pieper C, Schmader K: The association of weight change in Alzheimer's disease with severity of disease and mortality: a longitudinal analysis. J Am Geriatr Soc 1998;46:1223-1227.
44.
Johnson DK, Wilkins CH, Morris JC: Accelerated weight loss may precede diagnosis in Alzheimer disease. Arch Neurol 2006;63:1312-1317.
45.
Isidori AM, Strollo F, Morè M, et al: Leptin and aging: correlation with endocrine changes in male and female healthy adult populations of different body weights. J Clin Endocrinol Metab 2000;85:1954-1962.
46.
Lambrinoudaki I, Christodoulakos G, Panoulis C, et al: Determinants of serum leptin levels in healthy postmenopausal women. J Endocrinol Invest 2003;26:1225-1230.
47.
Gannagé-Yared MH, Khalife S, Semaan M, et al: Serum adiponectin and leptin levels in relation to the metabolic syndrome, androgenic profile and somatotropic axis in healthy non-diabetic elderly men. Eur J Endocrinol 2006;155:167-176.
48.
Fatima W, Shahid A, Imran M, et al: Leptin deficiency and leptin gene mutations in obese children from Pakistan. Int J Pediatr Obes 2011;6:419-427.
49.
Farooqi IS, Wangensteen T, Collins S, et al: Clinical and molecular genetic spectrum of congenital deficiency of the leptin receptor. N Engl J Med 2007;356:237-247.
50.
Paz-Filho GJ, Babikian T, Asarnow R, et al: Leptin replacement improves cognitive development. PLoS One 2008;3:e3098.
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.